Biodistribution of PEG- & BP-PEG-Au NPs



Cole et al., Acta Biomaterialia, 2018



Renal Clearance (Glomerular Filtration)



Liu et al., Mater. Today, 2013



Hepatobiliary Clearance



Zhang et al., J. Controlled Release, 2016



Passive Versus Active Targeting



Cole et al., Nanomedicine, 2015



Targeting Nanoparticles

Passive Targeting: accumulation of NPs due to physiological effects

- size, molecular weight
- enhanced permeation and retention (EPR) effect



Albanese et al., Annu. Rev. Biomed. Eng., 2012



Targeting Nanoparticles

Active Targeting: binding of a functional molecule to specific sites

- ligands (e.g., -COOH, -NH₂, -PO(OH)₂, etc.)
- biomolecules (e.g., folic acid, heparin, bombesin, insulin, etc.)
 - antibodies (e.g., anti-HER, anti-EGFR, anti-CD4, etc.)



Reuveni et al., Int. J. Nanomed., 2011



Targeting Nanoparticles

Active Targeting: binding of a functional molecule to specific sites

- ligands (e.g., -COOH, -NH₂, -PO(OH)₂, etc.)
- proteins
- antibodies e.g., SiO₂ coated Au nanoshells functionalized with anti-HER-2 to target surface receptors overexpressed in breast cancer cells for photothermal ablation *Lowery et al., Int. J. Nanomed.*, 2006







Cellular Uptake of Au NPs





Cellular Uptake of HfO₂ NPs

As-prepared HfO₂ NPs



Uptake in HeLa cells by macropinocytosis

McGinnity et al., J. Biomed. Mater. Res B, in review



Targeted Labeling of Damaged Bone Tissue



Ross et al., J. Biomed. Mater. Res., 2011, JNR, 2012



Functionalized Au NP Binding to HA

- used single crystal HA whiskers, 5.63 m²/g (BET) Roeder et al., 2006
- incubated in functionalized Au NP solutions for varying time, concentration, and media (DI H₂O, PBS, FBS)
- measured supernatant [Au] using ICP-OES
- modeled Langmuir binding isotherms



Ross et al., J. Biomed. Mater. Res., 2011



Binding Affinity to HA



Ross et al., J. Biomed. Mater. Res., 2011



Functionalized Au NP Binding to HA

binding constants in DI water	V -	V_{max} [S]
determined from Langmuir isotherms	v –	K + [S]

Group	K (mg/L)	V _{max} (mg/g)	V _{max} * (mg/m ²)	R^2
GA-Au NPs	0.69	1.20	0.21	0.88
PA-Au NPs	0.25	0.48	0.09	0.69
BP-Au NPs	3.40	7.75	1.38	0.95
Au NPs	2.14	0.39	0.07	0.75

Recall that BP exhibited ~50% lower surface density on Au NPs compared to GA and PA.

Ross et al., J. Biomed. Mater. Res., 2011



BP-Au NP Binding Affinity to HA



http://www.nd.edu/~amebio

Effects of Au NP Size

	Reference	Size (nm)	# Au NPs/cell	ng Au NPs/cell
argeting to cells		14	$3 \cdot 10^{3}$	8.31.10 ⁻⁸
	Chithrani et al. 2006	30	$4.5 \cdot 10^3$	$1.23 \cdot 10^{-6}$
	Citrate-stabilized Au NPs	50	6 ·10 ³	$7.58 \cdot 10^{-6}$
	HeLa cells	74	$4 \cdot 10^{3}$	$1.64 \cdot 10^{-5}$
		100	$2 \cdot 10^{3}$	2.02 ·10 ⁻⁵
Passive t	Xu et al. 2009	4	1.10 ⁷	6.46·10 ⁻⁶
	2-mercaptosuccinic acid	20	$1 \cdot 10^5$	$8.08 \cdot 10^{-6}$
	stabilized Au NPs	40	$2 \cdot 10^4$	1.29·10 ⁻⁵
	HeLa cells	60	$1 \cdot 10^4$	2.18 ·10 ⁻⁵
Active targeting to mineral substrate	Reference	Size (nm)	# Au NPs/g mineral	mg Au NPs/g mineral
	D	5	9.3 ·10 ¹⁵	11.0
	Koss <i>et al.</i> 2014	13	$5.1 \cdot 10^{14}$	11.3
	Bisphosphonate	35	$7.0 \cdot 10^{13}$	29.3
	Tuncuonanzou Au MI S	76	$1.6 \cdot 10^{13}$	62.5





Au NP (Non-)Toxicity



Dosing studies are critical to determine the minimum dose required to enhance contrast without inducing cytotoxicity.

Cole et al., Nanomedicine, 2015

